Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.

被引：0

作者：

Rha, Sun Young

Revil, Cedric

Valderrama, Adriana

Wang, Liya

Andre, Manon

McCarthy, Grant

Young, Kate

机构：

[1] Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea

[2] MSD Zurich, Zurich, Switzerland

[3] Merck & Co Inc, Rahway, NJ USA

[4] AIXIAL Grp, Paris, France

[5] MSD UK Ltd, London, England

来源：

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：354 / 354

页数：1